Research ExplorerPublicationsAssociation between age and efficacy of first-line immunothe...

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

Standard

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. / Yanagisawa, Takafumi; Quhal, Fahad; Kawada, Tatsushi; Bekku, Kensuke; Laukhtina, Ekaterina; Rajwa, Pawel; von Deimling, Markus; Chlosta, Marcin; Pradere, Benjamin; Karakiewicz, Pierre I; Mori, Keiichiro; Kimura, Takahiro; Schmidinger, Manuela; Shariat, Shahrokh F.

In: IMMUNOTHERAPY-UK, Vol. 15, No. 15, 10.2023, p. 1309-1322.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Yanagisawa, T, Quhal, F, Kawada, T, Bekku, K, Laukhtina, E, Rajwa, P, von Deimling, M, Chlosta, M, Pradere, B, Karakiewicz, PI, Mori, K, Kimura, T, Schmidinger, M & Shariat, SF 2023, 'Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis', IMMUNOTHERAPY-UK, vol. 15, no. 15, pp. 1309-1322. https://doi.org/10.2217/imt-2023-0039

APA

Yanagisawa, T., Quhal, F., Kawada, T., Bekku, K., Laukhtina, E., Rajwa, P., von Deimling, M., Chlosta, M., Pradere, B., Karakiewicz, P. I., Mori, K., Kimura, T., Schmidinger, M., & Shariat, S. F. (2023). Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. IMMUNOTHERAPY-UK, 15(15), 1309-1322. https://doi.org/10.2217/imt-2023-0039

Vancouver

Yanagisawa T, Quhal F, Kawada T, Bekku K, Laukhtina E, Rajwa P et al. Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. IMMUNOTHERAPY-UK. 2023 Oct;15(15):1309-1322. https://doi.org/10.2217/imt-2023-0039

Bibtex

@article{089565d732e044fdbba6b3ac14c98217,
title = "Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis",
abstract = "Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.",
author = "Takafumi Yanagisawa and Fahad Quhal and Tatsushi Kawada and Kensuke Bekku and Ekaterina Laukhtina and Pawel Rajwa and {von Deimling}, Markus and Marcin Chlosta and Benjamin Pradere and Karakiewicz, {Pierre I} and Keiichiro Mori and Takahiro Kimura and Manuela Schmidinger and Shariat, {Shahrokh F}",
year = "2023",
month = oct,
doi = "10.2217/imt-2023-0039",
language = "English",
volume = "15",
pages = "1309--1322",
journal = "IMMUNOTHERAPY-UK",
issn = "1750-743X",
publisher = "Future Medicine Ltd",
number = "15",

}

RIS

TY - JOUR

T1 - Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

AU - Yanagisawa, Takafumi

AU - Quhal, Fahad

AU - Kawada, Tatsushi

AU - Bekku, Kensuke

AU - Laukhtina, Ekaterina

AU - Rajwa, Pawel

AU - von Deimling, Markus

AU - Chlosta, Marcin

AU - Pradere, Benjamin

AU - Karakiewicz, Pierre I

AU - Mori, Keiichiro

AU - Kimura, Takahiro

AU - Schmidinger, Manuela

AU - Shariat, Shahrokh F

PY - 2023/10

Y1 - 2023/10

N2 - Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

AB - Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

U2 - 10.2217/imt-2023-0039

DO - 10.2217/imt-2023-0039

M3 - SCORING: Review article

C2 - 37694583

VL - 15

SP - 1309

EP - 1322

JO - IMMUNOTHERAPY-UK

JF - IMMUNOTHERAPY-UK

SN - 1750-743X

IS - 15

ER -